A comprehensive analysis of attention-deficit/hyperactivity disorder (ADHD) across Asia has identified ages 10 to 14 as the period when the disorder’s impact on daily functioning is greatest. The study, Published (DOI: 10.1007/s12519-026-01091-w) online on October 9, 2026, in World Journal of Pediatrics, examined 34 countries over more than three decades and found that ADHD-related disability remained concentrated in childhood and adolescence, with consistently higher rates among males.
Researchers from Kyung Hee University College of Medicine in Seoul, South Korea, and collaborating institutions used the Global Burden of Disease Study 2023 to analyze ADHD-related years lived with disability (YLDs) from 1990 to 2023. YLDs measure time lived with health-related disability, capturing the broader impact of ADHD beyond simple case counts. The team compared patterns by age, sex, region, socioeconomic development, and pandemic period.
The results showed marked regional heterogeneity rather than a uniform Asia-wide pattern. East Asia carried the highest regional burden and followed an upward trend, with Japan and China recording the largest national estimates. In contrast, Southeast Asia moved in the opposite direction and declined over the study period. Across all regions, ADHD-related disability peaked at ages 10–14 and then declined progressively; this age peak was particularly pronounced in East Asia. Males consistently had higher rates than females across regions and age groups.
The study also compared changes among children aged 0–14 before the pandemic (2015–2019) and during the subsequent period (2019–2023). Most countries showed increases, with the Republic of Korea shifting from a decline to a marked rise, although the authors cautioned that these patterns cannot establish that the pandemic caused the increase. Higher Socio-demographic Index (SDI) was associated with higher estimated ADHD disability, a relationship that may partly reflect differences in recognition and access to diagnosis rather than underlying disease alone.
The authors emphasized that the central message is not simply that some countries have higher ADHD estimates than others, but that the burden follows recognizable patterns that can inform support. They said the concentration of disability in early adolescence makes timely recognition especially important, while the consistently higher estimates among males should not obscure girls whose symptoms may be less readily noticed. They also stressed that differences between countries require careful interpretation, as better detection, health service access, and reporting can influence estimated burden.
These findings have practical implications for schools, clinicians, and policymakers. Schools can train teachers to recognize diverse ADHD presentations—including less obvious inattentive symptoms in girls—and strengthen referral pathways, classroom management, and social–emotional learning, especially around ages 10–14. Clinicians can prioritize early assessment in this age group, attend to sex-specific symptom profiles, integrate screening into primary care, and link families to evidence-based behavioral support. Policymakers can use these regional patterns to target resources, emphasize early identification and timely treatment, and expand school- and primary-care-based services where specialist capacity is limited. Because estimates are modeled and shaped by diagnostic and reporting differences, they should guide planning and monitoring rather than rank health systems.
